NCT00003042 2026-02-20
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
City of Hope Medical Center
Phase 2 Completed
Clinical Trials
285 trialsNCT04024462 2026-02-20
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT03301350 2026-02-13
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT01796197 2026-02-05
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05114720 2025-12-17
Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer
Sun Yat-sen University
Phase 3 Completed
NCT02654119 2025-12-12
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
Phase 2 Completed
NCT02950259 2025-12-03
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
Providence Health & Services
Phase 1 Completed
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT00861705 2025-09-30
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT06155331 2025-08-19
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Tanta University
Phase 2 Completed
NCT01275677 2025-07-14
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01354522 2025-06-15
TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer
Peking Union Medical College Hospital
Phase 3 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT01670500 2025-04-09
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT01779206 2025-04-08
ADAPT
West German Study Group
Phase 2/3 Completed
NCT02214381 2025-02-27
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
West German Study Group
Phase 3 Completed
NCT04109066 2025-01-08
CheckMate 7FL
Bristol-Myers Squibb
Phase 3 Completed
NCT04319757 2024-12-05
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Acepodia Biotech, Inc.
Phase 1 Completed
NCT03356860 2024-11-20
B-IMMUNE
Grand Hôpital de Charleroi
Phase 1/2 Completed
NCT02229084 2024-11-07
Vaccination of High Risk Breast Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT02938442 2024-11-07
Vaccination of Triple Negative Breast Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT03013504 2024-11-06
TROIKA
Prestige Biopharma Limited
Phase 3 Completed
NCT03726879 2024-11-05
IMpassion050
Hoffmann-La Roche
Phase 3 Completed
NCT00719173 2024-11-04
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT03164993 2024-10-15
ALICE
Oslo University Hospital
Phase 2 Completed
NCT03409198 2024-10-15
ICON
Oslo University Hospital
Phase 2 Completed
NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT01606241 2024-08-21
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 1 Completed
NCT03425656 2024-06-28
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
AryoGen Pharmed Co.
Phase 3 Completed
NCT03493854 2024-06-26
FeDeriCa
Hoffmann-La Roche
Phase 3 Completed
NCT06373744 2024-04-18
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
Sun Yat-sen University
Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT00003782 2024-03-21
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
NSABP Foundation Inc
Phase 3 Completed
NCT00036868 2024-03-08
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03752723 2024-03-05
KEYNOTE-899
Genexine, Inc.
Phase 1/2 Completed
NCT02954055 2024-02-26
METEORA-II
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT00712881 2024-02-23
Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00630032 2024-02-21
TavIx
UNICANCER
Phase 3 Completed
NCT02583828 2024-02-07
Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients
Capital Medical University
Phase NA Completed
NCT04350021 2024-01-17
METRO
Vastra Gotaland Region
Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT00577122 2023-10-16
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Indiana University
Phase 2 Completed
NCT01106898 2023-09-28
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
University of Nebraska
Phase 2 Completed
NCT00591851 2023-09-25
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT00146562 2023-08-02
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00003927 2023-07-05
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
City of Hope Medical Center
Phase 1 Completed
NCT00093834 2023-07-03
Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00309478 2023-06-29
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT00003519 2023-06-15
Combination Chemotherapy in Treating Women With Breast Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed